Biosenors nets CE Mark for smaller diameter DES
Biosensors International Group has received CE Mark approval for a 2.25-mm diameter version of its BioMatrix drug-eluting stent (DES) system, further expanding the currently available range of 2.5-mm to 4.0-mm stent diameters.
The new addition to the BioMatrix portfolio offers a major opportunity to increase market penetration, as an estimated 12 to 15 percent of PCI involve blood vessels with diameters of 2.5 mm or less, according to the Singapore-based company.
BioMatrix was originally launched in Europe in April 2008, with a proprietary coating formulation consisting of an abluminal biodegradable polymer and the Biolimus A9 drug, Biosensors. BioMatrix is now available in varying international markets outside of China, the U.S. and Japan.
The new addition to the BioMatrix portfolio offers a major opportunity to increase market penetration, as an estimated 12 to 15 percent of PCI involve blood vessels with diameters of 2.5 mm or less, according to the Singapore-based company.
BioMatrix was originally launched in Europe in April 2008, with a proprietary coating formulation consisting of an abluminal biodegradable polymer and the Biolimus A9 drug, Biosensors. BioMatrix is now available in varying international markets outside of China, the U.S. and Japan.